Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.
A review of HIV drugs in development that summarizes the most exciting new research over the previous year.
Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.
Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.
In the last two decades, antiretroviral therapy has dramatically improved the health of people living with HIV. Let’s take a brief look at the past and present before we look forward to HIV treatment in 2020.
In this interview, Joel E. Gallant, M.D., M.P.H., discusses new HIV drugs in the pipeline and the lack of young people becoming HIV care specialists.
Asier Sáez-Cirión, Ph.D., of the Institut Pasteur in Paris, sits down with IFARA to talk about his case study of a French teenager who has achieved HIV remission for 12 years.
A long-term aspirational goal is the elimination of HIV. In 1996, highly active antiretroviral therapy was thought to constitute a cure. Then latency was discovered to be a cure barrier. Today, achieving long-term remission of the virus is considered...